Health & Science | The Lee Company’s Post

Exciting news in the fight against sickle cell disease! The FDA has approved the first-ever CRISPR gene-editing treatment for this debilitating condition. This groundbreaking therapy, called Casgevy, offers a potentially curative option for patients suffering from sickle cell disease. Casgevy works by editing a specific gene that causes the production of abnormal red blood cells. These abnormal cells are the hallmark of sickle cell disease and lead to a range of painful and life-threatening complications. Clinical trials have shown Casgevy to be highly effective, offering patients the chance for a normal, healthy life. While this complex and expensive treatment will initially be available to a limited number of individuals, it marks a significant milestone in the fight against sickle cell disease. #CRISPR #lifescience